|1.||Steukers, Lennert: 1 article (02/2012)|
|2.||Van de Walle, Gerlinde R: 1 article (02/2012)|
|3.||Goris, Nesya: 1 article (02/2012)|
|4.||Croubels, Siska: 1 article (02/2012)|
|5.||Yang, Xiao-Yun: 1 article (02/2012)|
|6.||Nauwynck, Hans J: 1 article (02/2012)|
|7.||Vandekerckhove, Annelies P: 1 article (02/2012)|
|8.||Glorieux, Sarah: 1 article (02/2012)|
|9.||Neyts, Johan: 1 article (02/2012)|
|10.||Hayashi, Kozaburo: 1 article (04/2008)|
02/01/2012 - "Our data demonstrate that A-5021 is a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus."
02/01/2001 - "When treatment was begun on day 1 or 2, A-5021 still afforded marked protection against the infection, whereas acyclovir was virtually devoid of any activity under these conditions. "
02/01/2001 - "When administered from day 0 to 4 p.i., A-5021 conferred complete protection against the infection (as assessed at 22 days p.i.), whereas acyclovir delayed virus induced mortality by only 5 days. "
06/01/1999 - "In mice with a cutaneous HSV-1 (KOS) infection, three times daily oral therapy with A-5021 at 25 mg/kg per day produced more significant reduction in severity of skin lesions than equivalent treatment with acyclovir or famciclovir. "
|3.||Herpesviridae Infections (Herpesvirus Infection)
|4.||Lung Neoplasms (Lung Cancer)